Express News | InnoCare Announces Clearance of Clinical Trial of Tyk2 Inhibitor Icp-332 by U.S. FDA

ReutersJun 11 02:37 ET

Innocare (09969) anti-CD19 monoclonal antibody is expected to be included in priority review for the treatment of this type of blood cancer.

Innocare (09969) has applied for priority review of injection of Tafasitamab.

Zhitong FinanceJun 4 02:10 ET

InnoCare Pharma CEO Boosts Shareholding to 7.16%

InnoCare Pharma (HKG:9969, SHA:688428) Chief Executive Officer Jisong Cui purchased 316,000 shares in the company, bringing her family's aggregate shareholding to 7.16%, according to a Friday filing w

MT NewswiresMay 31 02:23 ET

InnoCare Pharma Grants Over 1.7 Million Shares Under Incentive Scheme

InnoCare Pharma (HKG:9969) granted 1,737,000 restricted shares to 47 employees under a share award scheme at 6.95 yuan each, according to a Thursday filing with the Hong Kong Stock Exchange. The compa

MT NewswiresMay 31 00:39 ET

InnoCare CEO Buys Shares, Signals Confidence

TipRanksMay 30 20:39 ET

Nuocheng Jianhua (09969.HK) received 316,000 shares from CEO and Executive Director Cui Jisong

Gelonghui, May 31, 丨 Nuocheng Jianhua (09969.HK) issued an announcement. Dr. Cui Jisong, CEO and executive director of the company, informed the company that he used personal funds to purchase a total of 316,000 shares in the open market on May 30, 2024. After the increase in shares, Dr. Cui and his family's total shares in the company accounted for about 7.16% of the total number of shares issued by the company as of the date of this announcement. Dr. Choi said that the increase in shares reflects full confidence in the company's pipeline product development and the company's commercialization prospects and growth potential. Dr. Choi does not rule out the possibility of further increasing the company's shares at the right time

Gelonghui FinanceMay 30 20:11 ET